Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer

Yongfu Li\textsuperscript{1,2}, Yuhan Wei\textsuperscript{1}, Wenjun Tang\textsuperscript{2}, Jingru Luo\textsuperscript{2}, Minghua Wang\textsuperscript{3}, Haifeng Lin\textsuperscript{2}, Hong Guo\textsuperscript{4}, Yuling Ma\textsuperscript{5}, Jun Zhang\textsuperscript{6}, Qin Li\textsuperscript{Corresp. 1}

\textsuperscript{1} Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
\textsuperscript{2} Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
\textsuperscript{3} Department of Pathology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China
\textsuperscript{4} Department of Surgery, Beijing Changping District Hospital of Traditional Medicine, Beijing, China
\textsuperscript{5} Department of Gynecology, Beijing Changping District Hospital of Traditional Medicine, Beijing, China
\textsuperscript{6} Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, US

Corresponding Author: Qin Li
Email address: oncologistinbj@163.com

Objective. To explore the association between the degree of fibrosis in fibrotic focus (FF) and the unfavorable clinicopathological prognostic features of breast cancer. Methods. 169 cases of breast invasive ductal carcinoma (IDC) were included in the study. Hematoxylin and eosin (H&E) staining was performed in the primary lesion of breast IDC and the degree of fibrosis in tumor-stromal FF was assessed. The association between the degree of fibrosis in FF and the well-known clinicopathologic features of breast cancer was investigated and the influence of the degree of fibrosis in FF on the survival was analyzed. Results. Tumor size $> 2\text{cm}$ ($P = 0.023$), vascular invasion ($P = 0.011$), lymphatic vessel invasion ($P < 0.001$) and HER-2\textsuperscript{+} ($P = 0.032$) were positively correlated with the degree of fibrosis in FF in breast IDC. The result of multivariate analysis showed that lymphatic vessel invasion was the only independent correlation factor of high fibrosis in FF in breast IDC (OR $= 3.82$, 95\% CI $1.13 \sim 12.82$, $P = 0.031$). The Nottingham prognostic index (NPI) of high fibrosis in FF was significantly higher than that of mild and moderate fibrosis in FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup ($P = 0.014, 0.039, \text{and } 0.018$; respectively). Conclusions. The high fibrosis in FF is closely associated with the strong invasiveness and the high malignancy of breast IDC. The degree of fibrosis in FF might be considered as a very practical and meaningful pathological feature of breast cancer.
Association between the degree of fibrosis in fibrotic focus and the unfavorable clinicopathological prognostic features of breast cancer

Yongfu Li¹,², Yuhan Wei¹, Wenjun Tang², Jingru Luo², Minghua Wang³, Haifeng Lin², Hong Guo⁴, Yuling Ma⁵, Jun Zhang⁶, Qin Li¹

¹Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
²Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China.
³Department of Pathology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China.
⁴Department of Surgery, Beijing Changping District Hospital of Traditional Medicine, Beijing, China.
⁵Department of Gynecology, Beijing Changping District Hospital of Traditional Medicine, Beijing, China.
⁶Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, US.

Corresponding Author:
Qin Li
No.95, Yongan Road, Xicheng District, Beijing, 100050, China.
E-mail address: oncologistinbj@163.com
**Abstract**

**Objective.** To explore the association between the degree of fibrosis in fibrotic focus (FF) and the unfavorable clinicopathological prognostic features of breast cancer.

**Methods.** 169 cases of breast invasive ductal carcinoma (IDC) were included in the study. Hematoxylin and eosin (H&E) staining was performed in the primary lesion of breast IDC and the degree of fibrosis in tumor-stromal FF was assessed. The association between the degree of fibrosis in FF and the well-known clinicopathologic features of breast cancer was investigated and the influence of the degree of fibrosis in FF on the survival was analyzed.

**Results.** Tumor size > 2cm ($P = 0.023$), vascular invasion ($P = 0.011$), lymphatic vessel invasion ($P < 0.001$) and HER-2+ ($P = 0.032$) were positively correlated with the degree of fibrosis in FF in breast IDC. The result of multivariate analysis showed that lymphatic vessel invasion was the only independent correlation factor of high fibrosis in FF in breast IDC (OR = 3.82, 95% CI 1.13 - 12.82, $P = 0.031$). The Nottingham prognostic index (NPI) of high fibrosis in FF was significantly higher than that of mild and moderate fibrosis in FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup ($P = 0.014$, 0.039, and 0.018; respectively).

**Conclusions.** The high fibrosis in FF is closely associated with the strong invasiveness and the high malignancy of breast IDC. The degree of fibrosis in FF might be considered as a very practical and meaningful pathological feature of breast cancer.

**Introduction**

Breast cancer is the most common female malignant tumor across the world (DeSantis et al. 2017). The prognosis of breast cancer is closely associated with various clinicopathological characteristics, such as age, tumor size, pathological type, lymph node metastasis status, histological grade, lymphovascular invasion, Ki-67 index, hormone receptor (HR) status, human epidermal growth factor receptor-2 (HER-2) expression, etc. These well-known pathological features have been widely used to make clinical treatment plans and predict the prognosis of breast cancer. However, the pathophysiology of breast cancer is not only closely related to the tumor cells, but also related to the tumor microenvironment which is composed of stromal cells, infiltrating immune cells, vasculature, extracellular matrix, and various cell signaling factors. Tumor microenvironment plays an important role in the genesis, development, invasion, metastasis, immune escape and chemotherapy resistance of tumor (Reisfeld 2013). FF is a pathological change in the tumor microenvironment of breast cancer, with an incidence of 18.7-53.0% (Colpaert et al. 2001; Hasebe et al. 1996; Kornegoor et al. 2012; Mujtaba et al. 2013; Van...
Hasebe described the pathologic features of FF in the breast cancer stroma in detail for the first time: a fibrotic lesion, with an appearance of scar or radiating expanding fibrosclerotic core, almost located in the center of carcinoma and consisted of variable amounts of collagen fibers and fibroblasts (Hasebe et al. 1996). At present, it is believed that the formation of FF is driven mostly by intratumoral hypoxia, which reflects the malignancy of carcinoma. Thus, FF is considered as a very practical and easily assessable clinicopathological parameter in breast cancer (Baak et al. 2005; Hasebe et al. 2000; Hasebe et al. 2002; Hasebe et al. 1997; Maiorano et al. 2010; Van den Eynden et al. 2007). According to the variable proportions of collagen fibers and fibroblasts, the degree of fibrosis in FF is classified into three categories: mild, moderate, and high (Hasebe et al. 1996; Van den Eynden et al. 2007). Lots of research fruits have been presented in the correlation between FF and the poor outcome in breast cancer. However, little is known about the association between the degree of fibrosis in FF and the prognosis of breast cancer so far. Whether the degree of fibrosis in FF could better reflect the prognosis of breast cancer than FF has become a research hotspot. Therefore, a retrospective study was conducted to explore the association between the degree of fibrosis in FF and the unfavorable clinicopathological prognostic features of breast cancer.

**Materials and methods**

**Cases.**

The objects of this study were 169 patients with primary breast cancer who underwent surgeries between January 1, 2016 and December 31, 2018 at the Second Affiliated Hospital of Hainan Medical University. Inclusion criteria: (1) female diagnosed with primary breast invasive ductal carcinoma (IDC); (2) IDC must be the principal component (> 50%) in mixed pathological type; (3) no distant metastasis; (4) no neoadjuvant therapy before surgery; (5) FF stained with H&E was present in the primary lesion of breast cancer. Exclusion criteria: (1) male breast cancer; (2) infiltrative specific breast cancer; (3) secondary carcinoma of mammary gland. All included cases were followed up once every three months by telephone.

**Ethical.**

The Second Affiliated Hospital of Hainan Medical University granted Ethical approval to carry out the study within its facilities (Application Ref: LW005). Our Institutional Review board waived the written consent, and the verbal consent was used.

**Materials.**

Personal information of included cases was collected accurately, including age, family tumor history, smoking history, and drinking history. The clinicopathological features were evaluated based on the pathological reports and the medical records, including tumor size, regional lymph
node metastasis status, stage, histological grade, vascular invasion, lymphatic vessel invasion, nervous infiltration, estrogen receptor (ER) status, progesterone receptor (PR) status, ki-67 index, HER-2 expression, etc. The measurement of tumor size was based on the largest diameter of invasive component in histological sections. The largest diameter of metastatic lesion > 0.2mm in axillary lymph node was defined as regional lymph node metastasis (Plichta et al. 2018). Disease stage was assessed according to the eighth edition of American Joint Committee on Cancer Staging Manual for breast cancer (Plichta et al. 2018). Histological grade was evaluated according to Nottingham modification of the Scarff-Bloom-Richardson histological grading system for invasive breast cancer (Elston & Ellis 1993). Stained with immunohistochemistry (IHC), the ER expression rate of tumor cells ≥ 1% was defined as positive ER expression (ER+), otherwise it was defined as negative ER expression (ER-). This criterion also was applied to the evaluation of the PR expression (PR+/-). The positive PR expression was classified into two categories: low (< 20%) and high (≥ 20%) (Prat et al. 2013). Positive hormone receptor expression (HR+) was defined by ER+ or/and PR+. In the selected area of slides with > 500 tumor cells, the percentage of tumor cells with positive Ki-67 expression (IHC) was defined as Ki-67 index. Ki-67 index was also classified into two categories: low (≤ 14%) and high (> 14%) (Goldhirsch et al. 2011). HER-2 expression status was defined according to the recommendations for HER-2 testing in breast cancer and classified into two categories: positive (HER-2+) and negative (HER-2-) (Wolff et al. 2013). Combining the immunohistochemical findings of ER, PR, HER-2, and Ki-67 index, breast cancer was classified into four molecular subtypes including Luminal A, Luminal B, HER-2 overexpression, and triple negative breast cancer (TNBC). NPI is a widely accepted clinicopathological scoring system for early breast cancer prognostication. NPI = Tumor size (cm) × 0.2 + Histological grade (1–3) + Lymph node stage (1–3) (Lee & Ellis 2008). Histological grade 1–3 was scored as 1–3 points, respectively. Lymph node stage 1 meant no node involved. Lymph node stage 2 meant 1–3 low axillary nodes involved or internal mammary node involved. Lymph node stage 3 meant ≥ 4 low axillary nodes involved and/or the apical axillary nodes involved or both low axillary nodes and internal mammary nodes involved. Lymph node stage 1–3 was scored as 1–3 points, respectively.

**Methods.**

All specimens of the primary lesion of breast cancer were fixed in 10% formalin and cut into 5μm-thick sections which were stained with H&E and analyzed by microscopic examination. Firstly, the location, size, appearance and components of FF should be observed under low power microscope. FF was mostly located in the center of the tumor. The size of FF was ≥ 1 mm, otherwise it could not be defined as FF. FF usually appeared as scar-like lesion (*Fig. 1A*) or irregular moth-eaten radiating fibrosclerotic core (*Fig. 1B*). Numerous tumor cells could be
observed frequently around FF. Besides, linear-growing tumor cells and tumor nests could be usually found in FF with diameter > 3mm. Coagulative necrosis could be present in some FFs. But coagulative necrosis without collagen fiber deposition and fibroblast proliferation was insufficient to be called FF. Sometimes, haemorrhage could be found in FF. Secondly, the components of FF were observed under high power microscope. FF was mainly composed of different proportions of fibroblasts and collagen fibers. The collagen fibers stained with H&E were thick and arranged closely in bundle. Different amounts of fibroblasts proliferating abnormally could be found among the collagen fibers. In addition, the densities of micro-vessels and micro-lymphatic vessels in FF were significantly higher than those in normal tissue.

Evaluating the degree of fibrosis in FF is the last but most important step. According to the proportion of fibroblasts and collagen fibers, FF was classified into three semi-quantitative categories (Van den Eynden et al. 2007): (1) mild fibrosis meant that FF consisted of a large number of fibroblasts and small amount of collagen fibers; (2) moderate fibrosis intermediated mild fibrosis and high fibrosis; (3) high fibrosis meant that FF was mainly composed of collagen fibers. Two experienced pathologists were involved in pathological examination and the other senior pathologist should reassess the degree of fibrosis in FF when the two pathologists did not agree on the conclusion.

Statistical analysis.

Statistical analyses were performed using IBM SPSS statistics software version 25.0. The mean age and the mean NPI were described by \( \bar{X} \pm SD \). Qualitative data of general and clinicopathologic features were described by case number, rate, and constituent ratio. Lower quartile (\( P_{25} \)), median (M), and upper quartile (\( P_{75} \)) were used to describe the distribution of NPI variables in different degrees of fibrosis in FF. The associations between the degree of fibrosis in FF and clinicopathologic features were analyzed by Mann-whitney U test and Jonckheere-Terpstra test. After stratifying the patients by clinicopathologic features, most NPI variables were skewed distribution. So Mann-whitney U test was performed to analyze the difference of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF. The factors significantly associated with the degree of fibrosis in FF in the univariate analyses (\( P < 0.05 \)) were entered together into ordinal logistic regression analysis. The remaining factors in the multivariate analysis were significant at \( P < 0.05 \). Generalized linear model was used to calculate the odds ratio (OR) and 95% confidence interval (95% CI). All analyses were two-sided and \( P < 0.05 \) was considered to indicate a statistically significant difference.

Results.

General characteristics of all cases.
Of the 169 cases, the mean age was 51.6 ± 10.0 (range, 28.0-80.0). 6 cases (3.6%) had family tumor histories, 21 cases (12.4%) had drinking histories, and none had smoking history.

Clinicopathological characteristics of all cases.
The main pathological pattern was IDC. 13 cases (7.7%) were mixed with one kind of infiltrative specific breast cancers, including mucinous carcinoma (3 cases, 1.8%), lobular carcinoma (2 cases, 0.12%), invasive papillary carcinoma (2 cases, 0.12%), apocrine carcinoma (2 cases, 0.12%), medullary carcinoma (1 case, 0.6%), neuroendocrine carcinoma (1 case, 0.6%), pleomorphic carcinoma (1 case, 0.6%), and basal carcinoid carcinoma (1 case, 0.6%). Other clinicopathologic characteristics are presented in Table 1.

The degree of fibrosis in FF.
FF had been observed in the primary lesion of each case. 11 cases (6.5%), 65 cases (38.5%), and 93 cases (55.0%) were evaluated as mild, moderate, and high fibrosis, respectively.

Representative histology of FF in breast IDC is shown in Fig. 1C~E.

Correlation between the clinicopathological characteristics and the degree of fibrosis in FF.
Tumor size > 2cm, vascular invasion, and lymphatic vessel invasion were significantly correlated with high fibrosis in FF (Fig. 1F and Fig. 2A~C). Age, lymph node metastasis, stage, histological grade, and nerve infiltration were not significantly associated with the degree of fibrosis in FF. Correlation between the clinicopathological characteristics and the degree of fibrosis in FF is presented in the Table 2.

Association between molecular subtypes and degree of fibrosis in FF.
Significant association was observed between HER-2+ and high fibrosis in FF ($P = 0.032$) and shown in Fig. 2D and Table 3. The other sub-factors of molecular subtypes (ER, PR, and Ki-67 index) and molecular subtypes were not significantly associated with the degree of fibrosis in FF (Table 3).

Multivariate analysis.
The factors, including tumor size, vascular invasion, lymphatic vessel invasion, and HER-2 expression status, were entered into the ordinal logistical analysis. Due to the missing data of clinicopathological features, 85 cases (50.3%) were excluded and 84 cases (49.7%) with complete data were finally included in the ordinal logistic regression analysis. The multivariate analysis result indicated that lymphatic vessel invasion was the only independent correlated factor of high fibrosis in FF (OR = 4.10, 95% CI 1.23 ~ 13.70, $P = 0.021$).

Comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF.
A total of 161 patients with complete data were eligible for NPI scoring. The mean NPI was 4.60±1.40. Due to the small number of patients (6.5%) with mild fibrosis in FF, we combined the patients with mild fibrosis and those with moderate fibrosis into one group. Finally, we divided the 161 cases into two groups, mild and moderate fibrosis group and high fibrosis group. No
significant difference was found between the two groups ($Z = -1.862$, $P = 0.063$) (Fig. 3). The cases were stratified by the clinicopathological characteristics to further analyze the differences of NPI variables between mild and moderate fibrosis group and high fibrosis group. In the no nerve infiltration subgroup, the no vascular infiltration subgroup, and the Luminal A subgroup, the NPI variables of high fibrosis in FF were significantly higher than those of mild and moderate fibrosis in FF ($P = 0.039, 0.014, \text{and } 0.018$; respectively) (Table 4 and Fig. 3).

**Discussion**

Our research found that tumor size $>2\text{cm}$, vascular invasion, lymphatic vessel invasion, and HER-2+ were positively correlated with the degree of fibrosis within FF in breast IDC by univariate analysis. Moreover, lymphatic vessel invasion was the only independent correlation factor of high fibrosis in FF in breast IDC by multivariate analysis. Although there was no significant difference between the NPI of mild and moderate fibrosis in FF and that of high fibrosis in FF, further analysis showed that the NPI variables of high fibrosis in FF were significantly higher than those of mild and moderate fibrosis in FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup. The above results indicated that the high fibrosis of FF was closely correlated with the aggressive clinicopathological characteristics of breast IDC and reflected the poor outcome of breast IDC with no vascular infiltration, no nerve infiltration or Luminal A subtype.

Hypoxia is the main cause of the fibrosis in tumor stroma (Daniel et al. 2019; Hoffmann et al. 2018). In hypoxia state, tumor cells secrete platelet derived growth factor (PDGF), transforming growth factor-β (TGF-β), and fibroblast growth factor-2 (FGF-2). All these cell factors act on the fibroblasts together, resulting in the deposition and remodeling of extracellular matrix and the graduate formation of FF in the tumor stroma. Besides, PDGF, TGF-β, and FGF-2, together with vascular endothelia growth factor (VEGFR) secreted by fibroblasts and tumor associated macrophages, promote the angiogenesis, lymphangiogenesis, and lymphovascular invasion (Shimada et al. 2017; Van den Eynden et al. 2007). The carcinoma-associated fibroblasts (CAFs), which are the main tumor interstitial cells and transforms from fibroblasts, result in the deposition of collagen and fibronectin in the extracellular stroma. It is considered that CAFs play an important function in the formation of FF and are closely related to the high malignancy of tumor (Balachander et al. 2018; Eiro et al. 2018; Reisfeld 2013; Yang et al. 2016). In addition, the fibrosis can inhibit T lymphocytes infiltration in tumor stroma and resist tumor immunity (Salmon et al. 2012). Therefore, FF forming in tumor stroma demonstrates the high aggressiveness of carcinoma (Van den Eynden et al. 2008). The tumor interstitial fibrosis associated with the adverse prognosis and anti-tumor drug resistance (Grasso et al. 2017).
has been observed in the carcinoma of breast cancer, pancreatic cancer (Thomas & Radhakrishnan 2019), colorectal cancer (Ikuta et al. 2018), and gastric cancer.

Hasebe et al (Hasebe et al. 1996) demonstrated that the histological grade and lymph node metastasis rate were higher in breast cancer with FF, especially in that with tumor size < 5cm. Jeong et al (Jeong et al. 2018) revealed that the FF was significantly associated with tumor size > 2cm, lymph node metastasis, poor differentiation, and vascular invasion in breast cancer. The studies mentioned above had indicated that FF was closely related with the adverse pathological characteristics of breast cancer. However, previous studies had rarely reported the association between the degree of fibrosis in FF and the pathological features of breast cancer, so we conducted this research. Our study found that the degree of fibrosis within FF in breast IDC with tumor size > 2cm was significantly higher than that with tumor size ≤ 2cm, indicating the more severe hypoxia occurred in larger tumors. Besides, our study also revealed that the degree of fibrosis within FF was significantly higher in breast cancer with vascular infiltration and lymphatic infiltration. It might be that the densities of blood vessels and lymphatics were higher in the tumor with high degree fibrosis of FF, increasing the probability of lymphovascular invasion. The result of multivariate analysis showed that lymphangitic infiltration was the only independent factor correlating with the high fibrosis in FF in patients with IDC. Due to the missing data of clinicopathological features, only 49.7% cases with complete data were finally included in the ordinal logistic regression analysis, which might prevent us from discovering more factors correlating with the high fibrosis within FF in multivariate analysis. To sum up, the high fibrosis of FF can predict the strong invasiveness and high malignancy of breast IDC.

The relation between FF and the sub-factors of molecular subtypes is not very clear now. Hasebe et al (Hasebe et al. 2000; Hasebe et al. 1996) showed that FF was significantly correlated with HER-2 protein overexpression in IDC. Mujtaba et al (Mujtaba et al. 2013) revealed that FF was negatively associated with HER-2 expression ($P = 0.021$) and Ki-67 index ($P = 0.001$) and positively associated with HR expression ($P = 0.007$). However, Jeong et al (Jeong et al. 2018) did not find that FF was related to the expression of HR, HER-2, and Ki-67. The results of the studies above were controversial, which may be caused by the followings. Firstly, there were other histopathological types of breast cancer besides IDC, which were included in Mujtaba’s and Jeong’s studies. And the molecular subtypes of varying histopathological types were distinct in breast cancer. Moreover, the testing methods and the diagnostic criterion of HER-2 expression and Ki-67 index were different from the current ones. The association between FF and molecular subtypes is also unclear. Mujtab et al (Mujtaba et al. 2013) demonstrated that the FF was more common in Luminal A subtype than in non-Luminal A subtype (n = 450, $P < 0.001$). But another study (Jeong et al. 2018) did not find the association between FF and molecular subtypes (n = 291, $P = 0.830$). The different conclusions might be due to the inconsistencies of baseline
characteristics of the cases included in the two studies. So more studies are needed in exploring
the association between FF and molecular subtypes of breast cancer.

Few studies were conducted on the relation between the degree of fibrosis in FF and the sub-
factors of molecular subtypes of breast cancer. Only Hasebe et al (Hasebe et al. 1996) revealed
that the HER-2 protein significantly overexpressed in the breast cancer with moderate and high
fibrosis in FF (90.9% vs. 41.7%, n = 153, \( P < 0.02 \)), compared with the breast cancer with mild
fibrosis in FF. The similar conclusion was drawn in our study (97.2% vs. 90.5%, n = 131, \( P =
0.032 \)). Thus it can be seen that moderate and high fibrosis of FF is correlated with the
invasiveness of breast cancer. Our study did not reveal any associations between the degree of
fibrosis and other sub-factors of molecular subtypes including ER, PR and Ki-67 index. In
addition, our result revealed that no association was found between the degree of fibrosis in FF
and molecular subtypes. The relation between the degree of fibrosis in FF and molecular
subtypes was not investigated in previous studies, so more studies are needed to explore the
question.

The associations between FF and the survival of breast cancer have been reported in many
studies. Hasebe et al (Hasebe et al. 1998) revealed that the presence of FF predicted higher risk
of recurrence and death in breast cancer with less than four lymph nodes metastases or stage
I ~ II B, compared with the absence of FF. Another study (Colpaert et al. 2001) including 104
cases of breast cancer with stage \( T_{1-2}N_{0}M_{0} \) showed that the median disease-free survival (DFS)
of cases with the presence of FF was significantly shorter than that with the absence of FF (25.0
months versus 91.5 months, \( P < 0.05 \)). Shimada et al (Shimada et al. 2017) demonstrated that the
higher risk of recurrence (HR, 7.8; 95%CI: 2.6-22.8; \( P < 0.001 \)) and the shorter median
progression-free survival (PFS) were found in breast cancer with the presence of FF. The studies
above had indicated that the presence of FF was associated with the poor outcome of breast
cancer. Therefore, FF was considered as a significant prognostic feature for breast cancer
(Hasebe et al. 1998; Mujtaba et al. 2013). On the basis of previous studies, we further explored
the correlation between the degree of fibrosis in FF and the long-term survival of breast IDC. All
the cases included in our study had not been followed up to the median survival time. Thus, the
short follow-up period led to the current inability of survival analysis, which was the greatest
deficiency of our study. NPI was adopted as an alternative survival indicator to investigate the
relation between the degree of fibrosis in FF and the long-term survival of breast cancer. NPI,
reported first by Lee et al, is used widely to predict the 10-year overall survival (OS) rate of early
breast cancer (Lee & Ellis 2008). NPI is a scoring system of clinicopathology containing tumor
size, histological grade, and lymph node stage. The NPI scores of 2.02~2.40, 2.41~3.40,
3.41~4.40, 4.41~5.40, 5.41~6.40, and 6.41~6.80 predict the 10-year overall survival rates of
96%, 93%, 81%, 74%, 55%, and 38%, respectively. According to the cutoffs of NPI score 3.40 and 5.40, the early breast cancer patients are stratified into good, moderate, and poor groups. The mean NPI in this study was 4.60 ± 1.40 and most cases were evaluated as moderate prognosis. Our study revealed that the NPI of high fibrosis in FF showed an upward tendency, compared with that of mild and moderate fibrosis in FF ($P = 0.063$). Further stratified analysis found that the NPI of high fibrosis in FF was significantly higher than that of mild and moderate fibrosis in FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup. In general, the clinicopathological features of no vascular infiltration, no nerve infiltration, and Luminal A subtype indicate favorable outcomes of breast IDC. The presence of FF with high fibrosis could indicate the relatively worse outcomes of cases with the favourable clinicopathological features of breast IDC mentioned above, which was found in our study. Thus it can be seen that the degree of fibrosis in FF could be used as a practical and meaningful pathological feature for predicting the survival outcome of early breast IDC.

**Conclusions**

In summary, our study demonstrated that the high fibrosis in FF was closely associated with the strong invasiveness and the high malignancy of breast IDC. There are some disadvantages in our study, including the small sample size, partial clinicopathological data missing, and short follow-up period. In the future study, expanding the sample size, collecting sufficient clinicopathological data, and extending follow-up time should be considered.

**Acknowledgements**

We thank Doctor Rongxin Yan for assistance of collecting pathological data, and thank Doctor Xiangtao Lin for taking the pathological pictures.

**References**

Baak JP, Colpaert CG, van Diest PJ, Janssen E, van Diermen B, Albernaz E, Vermeulen PB, and Van Marck EA. 2005. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 41:2093-2101 DOI: 10.1016/j.ejca.2005.03.038.

Balachander GM, Talukdar PM, Debnath M, Rangarajan A, and Chatterjee K. 2018. Inflammatory Role of Cancer-Associated Fibroblasts in Invasive Breast Tumors Revealed Using a Fibrous Polymer Scaffold. ACS Appl Mater Interfaces 10:33814-33826 DOI: 10.1021/acsami.8b07609.

Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, and Van
Marck E. 2001. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an
independent predictor of early distant relapse in lymph node-negative breast cancer
patients. Histopathology 39:416-425.

Daniel SK, Sullivan KM, Labadie KP, and Pillarisetty VG. 2019. Hypoxia as a barrier to
immunotherapy in pancreatic adenocarcinoma. Clin Transl Med 8:10 DOI:
10.1186/s40169-019-0226-9.

DeSantis CE, Ma J, Goding Sauer A, Newman LA, and Jemal A. 2017. Breast cancer statistics,
2017, racial disparity in mortality by state. CA Cancer J Clin 67:439-448 DOI:
10.3322/caac.21412.

Eiro N, Gonzalez L, Martinez-Ordonez A, Fernandez-Garcia B, Gonzalez LO, Cid S,
Dominguez F, Perez-Fernandez R, and Vizoso FJ. 2018. Cancer-associated fibroblasts
affect breast cancer cell gene expression, invasion and angiogenesis. Cell Oncol (Dordr)
41:369-378 DOI: 10.1007/s13402-018-0371-y.

Elston EW, and Ellis IO. 1993. Method for grading breast cancer. J Clin Pathol 46:189-190.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, and Panel m. 2011.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St.
Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
2011. Ann Oncol 22:1736-1747 DOI: 10.1093/annonc/mdr304.

Grasso C, Jansen G, and Giovannetti E. 2017. Drug resistance in pancreatic cancer: Impact of
altered energy metabolism. Crit Rev Oncol Hematol 114:139-152 DOI:
10.1016/j.critrevonc.2017.03.026.

Hasebe T, Mukai K, Tsuda H, and Ochiai A. 2000. New prognostic histological parameter of
invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus.
Pathol Int 50:263-272.

Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, and Ochiai A. 2002. Prognostic significance
of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational
study. Mod Pathol 15:502-516 DOI: 10.1038/modpathol.3880555.

Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Iwai M, Imoto S, and Mukai K. 1996. Fibrotic
focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J
Cancer Res 87:385-394.

Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, and Mukai K. 1998.
Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant
histopathological prognostic parameter for predicting the long-term survival of the
patients. Breast Cancer Res Treat 49:195-208.

Hasebe T, Tsuda H, Tsubono Y, Imoto S, and Mukai K. 1997. Fibrotic focus in invasive ductal
carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence
and tumor death within three years after the initial operation. Jpn J Cancer Res 88:590-
599.

Hoffmann C, Mao X, Brown-Clay J, Moreau F, Al Absi A, Wurzer H, Sousa B, Schmitt F,
Berchem G, Janji B, and Thomas C. 2018. Hypoxia promotes breast cancer cell invasion
through HIF-1alpha-mediated up-regulation of the invadopodial actin bundling protein
Ikuta D, Miyake T, Shimizu T, Sonoda H, Mukaisho KI, Tokuda A, Ueki T, Sugihara H, and Tani M. 2018. Fibrosis in metastatic lymph nodes is clinically correlated to poor prognosis in colorectal cancer. Oncotarget 9:29574-29586 DOI: 10.18632/oncotarget.25636.

Jeong YJ, Park SH, Mun SH, Kwak SG, Lee SJ, and Oh HK. 2018. Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer. Oncol Lett 15:2431-2440 DOI: 10.3892/ol.2017.7617.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, Hinrichs B, and van Diest PJ. 2012. Fibrotic focus and hypoxia in male breast cancer. Mod Pathol 25:1397-1404 DOI: 10.1038/modpathol.2012.101.

Lee AH, and Ellis IO. 2008. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 14:113-115 DOI: 10.1007/s12253-008-9067-3.

Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsh A, and Coates AS. 2010. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 121:211-218 DOI: 10.1007/s10549-009-0360-y.

Mujtaba SS, Ni YB, Tsang JY, Chan SK, Yamaguchi R, Tanaka M, Tan PH, and Tse GM. 2013. Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers. Ann Surg Oncol 20:2842-2849 DOI: 10.1245/s10434-013-2955-0.

Plichta JK, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Rosenberger LH, Hyslop T, and Hwang ES. 2018. Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. Ann Surg. DOI: 10.1097/SLA.0000000000003071.

Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyllesdesley S, Gelmon K, Bernard PS, Nielsen TO, and Perou CM. 2013. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203-209 DOI: 10.1200/JCO.2012.43.4134.

Reisfeld RA. 2013. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 18:115-133.

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mamichouaib F, and Donnadieu E. 2012. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122:899-910 DOI: 10.1172/JCI45817.

Shimada H, Hasebe T, Sugiyama M, Shibasaki S, Sugitani I, Ueda S, Gotoh Y, Yasuda M, Arai E, Osaki A, and Saeki T. 2017. Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast. Pathol Int 67:331-341 DOI: 10.1111/pin.12550.

Thomas D, and Radhakrishnan P. 2019. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer 18:14 DOI: 10.1186/s12943-018-0927-5.

Van den Eynden GG, Colpaert CG, Couvelard A, Pezzella F, Dirix LY, Vermeulen PB, Van...
Marck EA, and Hasebe T. 2007. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology 51:440-451 DOI: 10.1111/j.1365-2559.2007.02761.x.

Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, and Foekens JA. 2008. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 14:2944-2952 DOI: 10.1158/1078-0432.CCR-07-4397.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, and College of American P. 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013 DOI: 10.1200/JCO.2013.50.9984.

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, Dang Y, Chu Y, Fan J, and He R. 2016. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res 76:4124-4135 DOI: 10.1158/0008-5472.CAN-15-2973.
Figure 1

Representative histology of fibrotic focus (FF) in breast invasive ductal carcinoma (IDC).

(A) A representative histology of FF with the appearance of scar-like lesion indicated by arrows [H&E; magnification, ×20]. (B) A representative histology of FF with the appearance of irregular moth-eaten radiating fibrosclerotic core indicated by arrows [H&E; magnification, ×20]. (C) FF with mild fibrosis showing high number of fibroblasts and small amount of collagen fibers in stroma [H&E; magnification, ×100]. (D) FF with moderate fibrosis intermediating between mild fibrosis and high fibrosis and numerous tumor nests in FF [H&E; magnification, ×100]. (E) FF with high fibrosis showing mostly hyalinized collagen fibers [H&E; magnification, ×100]. (F) High fibrosis and peripheral vascular invasion indicated by the arrow [H&E; magnification, ×100]. Photograph credit: Doctor Xiangtao Lin.
Manuscript to be reviewed
Figure 2

The distribution of different degrees of fibrosis in FF in different clinicopathologic features.

(A) The comparison of the proportions of different degrees of fibrosis in FF between $T \leq 2\text{cm}$ ($T_1$) and $T > 2\text{cm}$ ($T_{2-3}$). (B) The comparison of the proportions of different degrees of fibrosis in FF between VI- and VI+. (C) The comparison of the proportions of different degrees of fibrosis in FF between LVI- and LVI+. (D) The comparison of the proportions of different degrees of fibrosis in FF between HER-2- and HER-2+. Notes: $T =$ tumor size; VI- = no vascular invasion; VI+ = vascular invasion; LVI- = no lymphatic vessel invasion; LVI+ = lymphatic vessel invasion.
Figure 3

The comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF.

Notes: VI- = no vascular invasion; NI- = no nervous infiltration.
Table 1 (on next page)

The characteristics of patients
Table 1: The characteristics of patients

| Clinicopathologic variables | n (%) | Clinicopathologic variables | n (%) |
|-----------------------------|-------|-----------------------------|-------|
| Age(years)                  |       | Nervous infiltration        |       |
| ≤ 50                        | 79 (46.7) | Yes                        | 32 (18.9) |
| >50                         | 90 (53.3) | No                         | 81 (47.9) |
| Tumor size                  |       | Unknown                     | 56 (33.2) |
| ≤ 2cm                       | 59 (34.9) | ER                         |       |
| > 2cm                       | 109 (64.5) | Positive                  | 108 (63.9) |
| Unknown                     | 1 (0.6) | Negative                   | 60 (35.5) |
| Lymph node                  |       | Unknown                     | 1 (0.6) |
| metastasis                  |       | PR                          |       |
| Yes                         | 90 (53.3) | Positive                  | 100 (59.1) |
| No                          | 76 (45.0) | Negative                  | 68 (40.2) |
| Unknown                     | 3 (1.7) | Unknown                    | 1 (0.7) |
| stage                       |       | Ki-67                       |       |
| I                           | 34 (20.1) | ≤14%                       | 35 (20.7) |
| II                          | 87 (51.5) | >14%                       | 129 (76.3) |
| III                         | 44 (26.0) | Unknown                    | 5 (3.0) |
| Unknown | 4 (2.4) | **Her-2** |
|---------|---------|-----------|
| **Histological grade** | | |
| I – II | 88 (52.1) | Negative | 95 (56.2) |
| III | 62 (36.7) | Unknown | 38 (22.5) |
| Unknown | 19 (11.2) | **Molecular subtype** |
| **Vascular invasion** | Luminal A | 16 (9.5) |
| Yes | 67 (39.6) | Luminal B | 93 (55.0) |
| No | 60 (35.5) | HER-2 |
| Unknown | 42 (24.9) | overexpression | 17 (10.1) |
| **Lymphatic vessel invasion** | TNBC | 24 (14.2) |
| Yes | 51 (30.1) | Unknown | 19 (11.2) |
| No | 64 (37.9) |
| Unknown | 54 (32.0) |
Table 2 (on next page)

The correlation between clinicopathological characteristics and degree of fibrosis in FF

*Mann-whitney U test  # Jonckheere-Terpstra test*
Table 2: The correlation between clinicopathological characteristics and degree of fibrosis in FF

| Clinicopathologic variables | Degree of fibrosis in FF | $Z/J$-value | $P$-value |
|-----------------------------|--------------------------|-------------|-----------|
|                             | Mild (n, %)               | Moderate (n, %) | High (n, %) |             |
| Age (n=169)                 |                          |              |            |             |
| $\leq$50 years              | 5 (45.5%)                 | 32 (49.2%)   | 42 (45.2%) | -0.397*     | 0.691       |
| $>$50 years                 | 6 (54.5%)                 | 33 (50.8%)   | 51 (54.8%) |             |             |
| Tumor size (n=168)         |                          |              |            |             |
| $\leq$2cm                   | 6 (54.6%)                 | 27 (42.2%)   | 26 (28.0%) | -2.276*     | 0.023       |
| $>$2cm                      | 5 (45.4%)                 | 37 (57.8%)   | 67 (72.0%) |             |             |
| Lymph node metastasis (n=166)|                        |              |            |             |
| No                          | 6 (54.5%)                 | 34 (53.1%)   | 36 (39.6%) | -1.746*     | 0.081       |
| Yes                         | 5 (45.5%)                 | 30 (46.9%)   | 55 (60.4%) |             |             |
| stage (n=165)               |                          |              |            |             |
| I                           | 4 (36.4%)                 | 16 (25.4%)   | 14 (15.4%) | 1.921*      | 0.055       |
| II                          | 4 (36.4%)                 | 34 (54.0%)   | 49 (53.8%) |             |             |
|                | I ~ II | III |
|----------------|-------|-----|
| Histological grade (n=150) |       |     |
| I ~ II          | 4 (40.0%) | 40 (67.8%) | 44 (54.3%) | -0.786* | 0.432 |
| III             | 6 (60.0%) | 19 (32.2%) | 37 (45.6%) |     |     |

|                | No | Yes |
|----------------|----|-----|
| Vascular invasion (n=127) |     |     |
| No             | 8 (80.0%) | 29 (52.7%) | 23 (37.1%) | -2.559* | 0.011 |
| Yes            | 2 (20.0%) | 26 (47.3%) | 39 (62.9%) |     |     |

|                | No | Yes |
|----------------|----|-----|
| Lymphatic vessel invasion (n=115) |     |     |
| No             | 10 (90.9%) | 32 (65.3%) | 22 (40.0%) | -3.523* | <0.001 |
| Yes            | 1 (9.1%) | 17 (34.7%) | 33 (60.0%) |     |     |

|                | No | Yes |
|----------------|----|-----|
| nervous infiltration (n=113) |     |     |
| No             | 9 (81.8%) | 38 (76.0%) | 34 (65.4%) | -1.419* | 0.156 |
| Yes            | 2 (18.2%) | 12 (24.0%) | 18 (34.6%) |     |     |

*Mann-whitney U test  
# Jonckheere-Terpstra test
Table 3 (on next page)

The association analysis of different variables between molecular subtypes and degree of fibrosis in FF

*Mann-whitney U test  # Jonckheere-Terpstra test*
Table 3:

The association analysis of different variables between molecular subtypes and degree of fibrosis in FF

| Variables | Mild | Moderate | High | Z/J-value | P-value |
|-----------|------|----------|------|-----------|---------|
|            | n (%) | n (%)    | n (%) |           |         |
| ER (n=168) |       |          |       |           |         |
| Negative   | 6 (54.6%) | 20 (31.2%) | 34 (36.6%) | -0.060* | 0.952   |
| Positive   | 5 (45.4%) | 44 (68.8%) | 59 (63.4%) |          |         |
| PR (n=168) |       |          |       |           |         |
| Negative   | 7 (63.6%) | 22 (34.4%) | 39 (41.9%) | -0.040* | 0.968   |
| Positive   | 4 (36.4%) | 42 (65.6%) | 54 (58.1%) |          |         |
| Ki-67 (n=164) |       |          |       |           |         |
| ≤14%       | 3 (27.3%) | 16 (26.2%) | 16 (17.4%) | -1.377*  | 0.168   |
| >14%       | 8 (72.7%) | 45 (73.8%) | 76 (82.6%) |          |         |
| HER-2 (n=131) |       |          |       |           |         |
| Negative   | 9 (90.0%) | 39 (79.6%) | 47 (65.3%) | -2.141*  | 0.032   |
| Positive   | 1 (10.0%) | 10 (20.4%) | 25 (34.7%) |          |         |

Molecular subtypes
|                      | Luminal A | Luminal B | HER-2 | TNBC |
|----------------------|-----------|-----------|-------|------|
|                      | 1 (9.1%)  | 9 (16.7%) | 6 (7.1%) | 0.572# | 0.568 |
| Luminal A            | 1 (9.1%)  | 9 (16.7%) | 6 (7.1%) |       |      |
| Luminal B            | 6 (54.5%) | 33 (61.1%)| 54 (63.5%)|       |      |
| HER-2                | 0 (0.0%)  | 2 (3.7%)  | 15 (17.6%)|       |      |
| HER-2 overexpression | 0 (0.0%)  | 2 (3.7%)  | 15 (17.6%)|       |      |
| TNBC                 | 4 (36.4%) | 10 (18.5%)| 10 (11.8%)|       |      |

4 *Mann-whitney U test
5 # Jonckheere-Terpstra test
Table 4 (on next page)

The comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF after stratification

*Mann-whitney U test # 5.15 was the median NPI. Since there were only 2 cases, the $P_{25}$ and $P_{75}$ could not be calculated.
Table 4:
The comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF after stratification

| Stratification | Degree of fibrosis in FF | Z-value* | P-value |
|----------------|--------------------------|----------|---------|
|                | Mild and moderate        |          |         |
|                | High                     |          |         |
|                | $P_{25}$, $M$, $P_{75}$ (n) |          |         |
| Age (years)    |                          |          |         |
| ≤50            | 3.36, 4.50, 5.40 (37)     | -0.930   | 0.352   |
| >50            | 3.40, 4.40, 5.20 (36)     | -1.690   | 0.091   |
| Tumor size     |                          |          |         |
| ≤2cm           | 3.30, 4.27, 5.20 (32)     | -0.299   | 0.765   |
| >2cm           | 3.60, 4.60, 5.60 (41)     | -1.448   | 0.148   |
| Lymph node     |                          |          |         |
| metastasis     |                          |          |         |
| No             | 3.29, 3.50, 4.40 (38)     | -0.696   | 0.486   |
| Yes            | 4.60, 5.36, 5.90 (35)     | -1.063   | 0.288   |
| stage          |                          |          |         |
| I              | 3.21, 3.36, 4.29 (20)     | -0.406   | 0.691   |
| II             | 3.58, 4.50, 5.15 (37)     | -0.465   | 0.642   |
| III            | 5.32, 5.80, 6.30 (16)     | -1.436   | 0.151   |
|                          | Histological grade | Vascular invasion | Lymphatic vessel invasion | Nervous infiltration | ER | PR | Ki-67 |
|--------------------------|--------------------|-------------------|---------------------------|----------------------|----|----|-------|
| **I ~ II**               | 3.32, 3.70, 5.00 (43) | 3.50, 4.50, 5.40 (43) | -1.517 | 0.129 |
| **III**                  | 4.50, 5.20, 5.60 (25) | 4.57, 5.60, 6.45 (37) | -1.443 | 0.149 |
| **No**                   | 3.31, 4.27, 4.95 (36) | 3.60, 5.00, 6.35 (21) | -2.458 | 0.014 |
| **Yes**                  | 3.58, 5.10, 5.70 (26) | 4.31, 4.93, 5.85 (38) | -0.616 | 0.538 |
| **No**                   | 3.36, 4.40, 5.18 (40) | 3.50, 5.00, 6.00 (21) | -1.709 | 0.087 |
| **Yes**                  | 3.58, 4.56, 5.70 (17) | 4.46, 5.18, 5.80 (32) | -1.441 | 0.150 |
| **No**                   | 3.37, 4.40, 5.20 (45) | 3.70, 4.80, 5.70 (32) | -2.063 | 0.039 |
| **Yes**                  | 3.35, 4.80, 5.65 (13) | 4.43, 5.20, 6.53 (16) | -0.430 | 0.446 |
| **Negative**             | 3.68, 5.00, 5.43 (26) | 4.53, 5.40, 6.30 (32) | -1.799 | 0.072 |
| **Positive**             | 3.30, 4.40, 5.00 (47) | 3.50, 4.47, 5.60 (56) | -1.060 | 0.289 |
| **Negative**             | 4.28, 4.68, 5.39 (28) | 4.57, 5.10, 6.20 (37) | -1.955 | 0.051 |
| **Positive**             | 3.30, 3.90, 5.25 (45) | 3.40, 4.40, 5.60 (51) | -0.962 | 0.336 |
| ≤14%         | 2.77, 3.40, 4.42 (17) | 3.33, 3.70, 4.58 (16) | -1.353 | 0.179 |
|--------------|----------------------|----------------------|--------|-------|
| >14%         | 3.65, 4.60, 5.40 (53) | 4.26, 4.96, 5.70 (71) | -1.519 | 0.129 |

**HER-2**

| Negative     | 3.39, 4.40, 5.32 (46) | 3.70, 4.50, 5.70 (43) | -1.450 | 0.147 |
|--------------|----------------------|----------------------|--------|-------|
| Positive     | 4.56, 5.20, 5.70 (11) | 4.32, 5.05, 5.80 (24) | -0.124 | 0.903 |

**Molecular subtypes**

| Luminal A    | 2.37, 3.08, 3.30 (9)  | 3.12, 4.05, 4.45 (6)  | -2.359 | 0.018 |
|--------------|----------------------|----------------------|--------|-------|
| Luminal B    | 3.48, 4.58, 5.43 (38) | 3.70, 4.50, 5.60 (51) | -0.183 | 0.855 |

**HER-2 overexpression**

| 5.15#(2)     | 4.93, 5.70, 6.58 (14) | -0.954 | 0.417 |

| TNBC         | 3.68, 4.50, 5.40 (14) | 4.10, 5.00, 7.55 (9) | -1.073 | 0.305 |

4 * Mann-whitney U test

5 # 5.15 was the median NPI. Since there were only 2 cases, the $P_{25}$ and $P_{75}$ could not be calculated.